화학요법제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Chemotherapy Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,411,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,823,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,604,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 최근 세계 화학요법제 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 촉진요인, 동향, 기회, 촉진요인, 도전 과제 등 중요한 시장 역학을 철저히 평가하고 시장 구조에 대한 심층적인 인사이트를 제공합니다. 이 보고서는 2025년부터 2032년까지 세계 화학요법제 시장의 예측 성장 궤적을 개괄하는 독점적인 데이터와 통계를 담고 있습니다.

주요 인사이트

• 화학요법제 시장 규모(2025년) : 561억 달러
• 예측 시장 규모(2032년) : 1,025억 달러
• 세계 시장 성장률(2025-2032년 CAGR) : 9.0%

화학요법제 시장 - 보고서 범위:

화학요법제는 암 치료에 필수적이며, 빠르게 분열하는 암세포를 표적으로 삼아 제거함으로써 효과를 발휘합니다. 이러한 약물은 수술, 방사선 요법, 면역요법과 같은 다른 치료와 함께 사용되어 환자의 예후를 개선합니다. 화학요법제 시장은 알킬화제, 대사길항제, 분열억제제, 토포이소머라제 억제제 등 다양한 종류의 약물을 제공하며 병원, 전문 암센터, 재택의료 현장에 대응하고 있습니다. 시장 성장의 원동력은 암 발병률 증가, 의료비 지출 증가, 약제제제의 발전에 따른 치료 효과 향상과 부작용 감소입니다.

시장 성장 촉진요인:

세계 화학요법제 시장은 전 세계 암 발병률 증가, 약물 개발의 발전, 표적 치료제에 대한 수요 증가 등 몇 가지 중요한 요인에 의해 주도되고 있습니다. 흡연, 식습관, 환경오염과 같은 생활습관 관련 위험요인과 함께 고령화 인구의 증가는 암 발병률 증가의 한 요인으로 작용하고 있으며, 이는 화학요법 치료에 대한 수요를 촉진하고 있습니다. 또한, 병용요법 및 맞춤의료의 개발로 환자 예후가 개선되면서 화학요법제의 채택이 확대되고 있습니다. 암 치료 인프라 구축과 연구비 증가를 위한 정부의 노력은 시장 확대를 더욱 촉진하고 있습니다.

시장 억제요인:

화학요법제 시장은 유망한 성장세를 보이고 있지만, 약물 독성, 높은 치료비, 엄격한 규제 요건 등의 문제에 직면해 있습니다. 메스꺼움, 탈모, 면역억제 등 화학요법에 따른 부작용은 종종 치료 중단으로 이어져 시장 도입에 영향을 미칩니다. 또한, 특히 중저소득 국가에서는 화학요법 약품의 높은 가격과 환자의 경제적 부담이 시장 침투에 큰 장벽이 되고 있습니다. 또한, 의약품 승인 절차의 장기화, 엄격한 안전성 가이드라인 준수 등 규제상의 문제도 시장 확대에 걸림돌이 되고 있습니다. 이러한 문제를 해결하기 위해서는 지지요법에 대한 투자 확대, 비용 효율적인 약물 처방, 규제 조화가 필요합니다.

시장 기회:

화학요법제 시장은 기술 발전, 의료 접근성 확대, 연구개발 투자 증가로 인해 큰 성장 기회를 맞이하고 있습니다. 부작용을 줄이고 효능을 높인 표적 화학요법제의 개발은 기술 혁신의 주요 분야입니다. 또한, 바이오시밀러 및 화학요법제 제네릭 의약품의 채택 확대로 구매하기 쉬운 가격대가 개선되어 시장 확대가 기대됩니다. 아시아태평양과 라틴아메리카의 신흥 시장은 헬스케어 인프라 투자 증가와 암 치료 옵션에 대한 인식이 높아지면서 유리한 기회를 제공하고 있습니다. 기업이 이러한 기회를 활용하고 시장 리더십을 유지하기 위해서는 전략적 제휴, 생명공학 기업과의 파트너십, 약물전달 메커니즘의 지속적인 발전이 필수적입니다.

본 보고서에서 다루는 주요 질문

• 세계 화학요법제 시장의 성장을 촉진하는 주요 요인은 무엇인가?
• 다양한 의료 환경에서 화학요법을 채택하는 원동력이 되는 약물의 종류와 용도는 무엇인가?
• 기술의 발전은 화학요법제 시장의 경쟁 구도를 어떻게 변화시키고 있는가?
• 화학요법제 시장에 기여하고 있는 주요 기업은 어디이며, 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계 화학요법제 시장의 새로운 트렌드와 향후 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위와 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 거시경제 요인
  • 세계의 부문별 전망
  • 세계의 GDP 성장 전망
• COVID-19의 영향 분석
• 예측요인 - 관련성과 영향

제3장 부가가치 인사이트

• 제품 채용 분석
• 규제 상황
• 질병 역학
• 밸류체인 분석
• 주요 거래와 합병
• PESTLE 분석
• Porter's Five Forces 분석

제4장 세계의 화학요법제 시장 전망:

• 주요 하이라이트
  • 시장 규모와 전년비 성장률
  • 절대적 수익 기회
• 시장 규모 분석과 예측
  • 과거 시장 규모 분석, 2019-2024년
  • 현재 시장 규모 분석과 예측, 2024-2032년
• 세계의 화학요법제 시장 전망 : 약물 종류
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 약물 종류별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 약물 종류별, 2024-2032년
    • 알킬화제
    • 항대사제
    • 항종양 항생제
    • 토포이소머라제 억제제
    • 유사분열 억제제
    • 식물 알칼로이드
    • 코르티코스테로이드
    • 기타 항종양제
  • 시장 매력 분석 : 의약품 클래스
• 세계의 화학요법제 시장 전망 : 적응증
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 적응증별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 적응증별, 2024-2032년
    • 폐암
    • 유방암
    • 대장암
    • 전립선암
    • 백혈병
    • 림프종
    • 난소암
    • 췌장암
    • 기타
  • 시장 매력 분석 : 적응증
• 세계의 화학요법제 시장 전망 : 투여 경로
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 투여 경로별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 투여 경로별, 2024-2032년
    • 경구
    • 비경구
    • 기타
  • 시장 매력 분석 : 투여 경로
• 세계의 화학요법제 시장 전망 : 제형
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 제형별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 제형별, 2024-2032년
    • 캡슐/정제
    • 주사
    • 기타
  • 시장 매력 분석 : 제형
• 세계의 화학요법제 시장 전망 : 유통 채널
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 유통 채널별, 2019-2024년
  • 현재 시장 규모 분석과 예측, 유통 채널별, 2024-2032년
    • 소매 약국
    • 병원 약국
    • 종양과 클리닉 및 점적 센터
    • 기타
  • 시장 매력 분석 : 유통 채널

제5장 세계의 화학요법제 시장 전망 : 지역

• 주요 하이라이트
• 지역별 시장 규모 과거 분석, 2019-2024년
• 현재 시장 규모 분석과 예측, 지역별, 2024-2032년
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장 매력 분석 : 지역

제6장 북미의 화학요법제 시장 전망:

제7장 유럽의 화학요법제 시장 전망:

제8장 동아시아의 화학요법제 시장 전망:

제9장 남아시아 및 오세아니아의 화학요법제 시장 전망:

제10장 라틴아메리카의 화학요법제 시장 전망:

제11장 중동 및 아프리카의 화학요법제 시장 전망:

제12장 경쟁 구도

• 시장 점유율 분석, 2024년
• 시장 구조
  • 시장별 경쟁 강도 매핑
  • 경쟁 대시보드
• 기업 개요(상세 - 개요, 재무, 전략, 최근 동향)
  • F. Hoffmann-La Roche Ltd
  • Celgene Corp
  • Novartis AG
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Sanofi
  • Pfizer Inc.
  • Eli Lilly &Company
  • ImClone Systems Inc.
  • GlaxoSmithKline
  • AstraZeneca
  • Schering-Plough
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals Industries
  • E. Hoffmann-La Roche Ltd
  • Merck &Co. Inc.
  • Chemo Espana SL
  • Amgen Inc
  • Bayer AG
  • Takeda Pharmaceutical Company Limited

제13장 부록

• 조사 방법
• 조사 가정
• 두문자어와 약어

ksm

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the worldwide market for chemotherapy drugs. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global chemotherapy drugs market from 2025 to 2032.

Key Insights:

• Chemotherapy Drugs Market Size (2025E): US$ 56.1Bn
• Projected Market Value (2032F):US$ 102.5Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 9.0%

Chemotherapy Drugs Market - Report Scope:

Chemotherapy drugs are essential in cancer treatment, working by targeting and eliminating rapidly dividing cancer cells. These drugs are used in combination with other treatments, including surgery, radiation therapy, and immunotherapy, to enhance patient outcomes. The chemotherapy drugs market caters to hospitals, specialty cancer centers, and homecare settings, offering a range of drug types, including alkylating agents, antimetabolites, mitotic inhibitors, and topoisomerase inhibitors. Market growth is driven by increasing cancer prevalence, rising healthcare expenditures, and advancements in drug formulations, enhancing treatment efficacy and reducing side effects.

Market Growth Drivers:

The global chemotherapy drugs market is propelled by several key factors, including the increasing global burden of cancer, advancements in drug development, and the rising demand for targeted therapies. The growing aging population, coupled with lifestyle-related risk factors such as smoking, poor diet, and environmental pollution, contributes to the rising incidence of cancer, fueling the demand for chemotherapy treatments. Additionally, the development of combination therapies and personalized medicine has improved patient outcomes, leading to wider adoption of chemotherapy drugs. Government initiatives aimed at improving cancer care infrastructure and increasing research funding further drive market expansion.

Market Restraints:

Despite promising growth prospects, the chemotherapy drugs market faces challenges related to drug toxicity, high treatment costs, and stringent regulatory requirements. The adverse side effects associated with chemotherapy, such as nausea, hair loss, and immune suppression, often lead to treatment discontinuation, impacting market adoption. Additionally, the high cost of chemotherapy drugs and the financial burden on patients, particularly in low- and middle-income countries, pose significant barriers to market penetration. Regulatory challenges, including lengthy drug approval processes and compliance with stringent safety guidelines, further hinder market expansion. Addressing these challenges requires increased investment in supportive care, cost-effective drug formulations, and regulatory harmonization.

Market Opportunities:

The chemotherapy drugs market presents significant growth opportunities driven by technological advancements, expanding healthcare access, and increasing R&D investments. The development of targeted chemotherapy drugs with reduced side effects and enhanced efficacy is a key area of innovation. Additionally, the growing adoption of biosimilars and generic chemotherapy drugs is expected to improve affordability and expand market reach. Emerging markets in Asia-Pacific and Latin America offer lucrative opportunities due to rising healthcare infrastructure investments and increasing awareness about cancer treatment options. Strategic collaborations, partnerships with biotechnology firms, and continuous advancements in drug delivery mechanisms are essential for companies to capitalize on these opportunities and maintain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the chemotherapy drugs market globally?
• Which drug types and applications are driving chemotherapy adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the chemotherapy drugs market?
• Who are the key players contributing to the chemotherapy drugs market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global chemotherapy drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global chemotherapy drugs market, including Pfizer Inc., Roche Holding AG, Bristol-Myers Squibb Company, and Novartis AG, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced chemotherapy solutions, including targeted therapies, antibody-drug conjugates, and nanoparticle-based drug delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with research institutions, hospitals, and regulatory agencies facilitate market access and promote drug adoption. Moreover, emphasis on clinical research, precision medicine, and patient-centric approaches fosters market growth and enhances treatment outcomes in the evolving oncology landscape.

Key Companies Profiled:

• Pfizer Inc.
• Roche Holding AG
• Bristol-Myers Squibb Company
• Novartis AG
• Eli Lilly and Company
• Sanofi S.A.
• Merck & Co., Inc.
• AstraZeneca PLC
• Amgen Inc.
• Bayer AG

Key Segments of Chemotherapy Drugs Industry Research

By Drug Class:

• Alkylating Agents
• Antimetabolites
• Anti-tumour Antibiotics
• Topoisomerase Inhibitors
• Mitotic Inhibitors
• Plant Alkaloids
• Corticosteroids
• Miscellaneous Antineoplastic

By Indication:

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma
• Ovarian Cancer
• Pancreatic Cancer

By Route of Administration:

• Oral
• Parenteral

By Dosage Form:

• Capsules/Tablets
• Injections

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Oncology Clinics & Infusion Centers

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Chemotherapy Drugs Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Product Adoption Analysis
• 3.2. Regulatory Landscape
• 3.3. Disease Epidemiology
• 3.4. Value Chain Analysis
• 3.5. Key Deals and Mergers
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Chemotherapy Drugs Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024-2032
• 4.3. Global Chemotherapy Drugs Market Outlook: Drug Class
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2024
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
    • 4.3.3.1. Alkylating Agents
    • 4.3.3.2. Antimetabolites
    • 4.3.3.3. Anti-tumour Antibiotics
    • 4.3.3.4. Topoisomerase Inhibitors
    • 4.3.3.5. Mitotic Inhibitors
    • 4.3.3.6. Plant Alkaloids
    • 4.3.3.7. Corticosteroids
    • 4.3.3.8. Miscellaneous Antineoplastic
  • 4.3.4. Market Attractiveness Analysis: Drug Class
• 4.4. Global Chemotherapy Drugs Market Outlook: Indication
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
  • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
    • 4.4.3.1. Lung Cancer
    • 4.4.3.2. Breast Cancer
    • 4.4.3.3. Colorectal Cancer
    • 4.4.3.4. Prostate Cancer
    • 4.4.3.5. Leukemia
    • 4.4.3.6. Lymphoma
    • 4.4.3.7. Ovarian Cancer
    • 4.4.3.8. Pancreatic Cancer
    • 4.4.3.9. Others
  • 4.4.4. Market Attractiveness Analysis: Indication
• 4.5. Global Chemotherapy Drugs Market Outlook: Route of Administration
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019-2024
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
    • 4.5.3.1. Oral
    • 4.5.3.2. Parenteral
    • 4.5.3.3. Others
  • 4.5.4. Market Attractiveness Analysis: Route of Administration
• 4.6. Global Chemotherapy Drugs Market Outlook: Dosage Form
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Dosage Form, 2019-2024
  • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
    • 4.6.3.1. Capsules/Tablets
    • 4.6.3.2. Injections
    • 4.6.3.3. Others
  • 4.6.4. Market Attractiveness Analysis: Dosage Form
• 4.7. Global Chemotherapy Drugs Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
    • 4.7.3.1. Retail Pharmacies
    • 4.7.3.2. Hospital Pharmacies
    • 4.7.3.3. Oncology Clinics & Infusion Centers
    • 4.7.3.4. Others
  • 4.7.4. Market Attractiveness Analysis: Distribution Channel

5. Global Chemotherapy Drugs Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Chemotherapy Drugs Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Drug Class
  • 6.2.3. By Indication
  • 6.2.4. By Route of Administration
  • 6.2.5. By Dosage Form
  • 6.2.6. By Distribution Channel
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 6.4.1. Alkylating Agents
  • 6.4.2. Antimetabolites
  • 6.4.3. Anti-tumour Antibiotics
  • 6.4.4. Topoisomerase Inhibitors
  • 6.4.5. Mitotic Inhibitors
  • 6.4.6. Plant Alkaloids
  • 6.4.7. Corticosteroids
  • 6.4.8. Miscellaneous Antineoplastic
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 6.5.1. Lung Cancer
  • 6.5.2. Breast Cancer
  • 6.5.3. Colorectal Cancer
  • 6.5.4. Prostate Cancer
  • 6.5.5. Leukemia
  • 6.5.6. Lymphoma
  • 6.5.7. Ovarian Cancer
  • 6.5.8. Pancreatic Cancer
  • 6.5.9. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 6.6.1. Oral
  • 6.6.2. Parenteral
  • 6.6.3. Others
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 6.7.1. Capsules/Tablets
  • 6.7.2. Injections
  • 6.7.3. Others
• 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 6.8.1. Retail Pharmacies
  • 6.8.2. Hospital Pharmacies
  • 6.8.3. Oncology Clinics & Infusion Centers
  • 6.8.4. Others
• 6.9. Market Attractiveness Analysis

7. Europe Chemotherapy Drugs Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Drug Class
  • 7.2.3. By Indication
  • 7.2.4. By Route of Administration
  • 7.2.5. By Dosage Form
  • 7.2.6. By Distribution Channel
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 7.4.1. Alkylating Agents
  • 7.4.2. Antimetabolites
  • 7.4.3. Anti-tumour Antibiotics
  • 7.4.4. Topoisomerase Inhibitors
  • 7.4.5. Mitotic Inhibitors
  • 7.4.6. Plant Alkaloids
  • 7.4.7. Corticosteroids
  • 7.4.8. Miscellaneous Antineoplastic
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 7.5.1. Lung Cancer
  • 7.5.2. Breast Cancer
  • 7.5.3. Colorectal Cancer
  • 7.5.4. Prostate Cancer
  • 7.5.5. Leukemia
  • 7.5.6. Lymphoma
  • 7.5.7. Ovarian Cancer
  • 7.5.8. Pancreatic Cancer
  • 7.5.9. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 7.6.1. Oral
  • 7.6.2. Parenteral
  • 7.6.3. Others
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 7.7.1. Capsules/Tablets
  • 7.7.2. Injections
  • 7.7.3. Others
• 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 7.8.1. Retail Pharmacies
  • 7.8.2. Hospital Pharmacies
  • 7.8.3. Oncology Clinics & Infusion Centers
  • 7.8.4. Others
• 7.9. Market Attractiveness Analysis

8. East Asia Chemotherapy Drugs Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Drug Class
  • 8.2.3. By Indication
  • 8.2.4. By Route of Administration
  • 8.2.5. By Dosage Form
  • 8.2.6. By Distribution Channel
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 8.4.1. Alkylating Agents
  • 8.4.2. Antimetabolites
  • 8.4.3. Anti-tumour Antibiotics
  • 8.4.4. Topoisomerase Inhibitors
  • 8.4.5. Mitotic Inhibitors
  • 8.4.6. Plant Alkaloids
  • 8.4.7. Corticosteroids
  • 8.4.8. Miscellaneous Antineoplastic
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 8.5.1. Lung Cancer
  • 8.5.2. Breast Cancer
  • 8.5.3. Colorectal Cancer
  • 8.5.4. Prostate Cancer
  • 8.5.5. Leukemia
  • 8.5.6. Lymphoma
  • 8.5.7. Ovarian Cancer
  • 8.5.8. Pancreatic Cancer
  • 8.5.9. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 8.6.1. Oral
  • 8.6.2. Parenteral
  • 8.6.3. Others
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 8.7.1. Capsules/Tablets
  • 8.7.2. Injections
  • 8.7.3. Others
• 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 8.8.1. Retail Pharmacies
  • 8.8.2. Hospital Pharmacies
  • 8.8.3. Oncology Clinics & Infusion Centers
  • 8.8.4. Others
• 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Chemotherapy Drugs Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Drug Class
  • 9.2.3. By Indication
  • 9.2.4. By Route of Administration
  • 9.2.5. By Dosage Form
  • 9.2.6. By Distribution Channel
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 9.4.1. Alkylating Agents
  • 9.4.2. Antimetabolites
  • 9.4.3. Anti-tumour Antibiotics
  • 9.4.4. Topoisomerase Inhibitors
  • 9.4.5. Mitotic Inhibitors
  • 9.4.6. Plant Alkaloids
  • 9.4.7. Corticosteroids
  • 9.4.8. Miscellaneous Antineoplastic
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 9.5.1. Lung Cancer
  • 9.5.2. Breast Cancer
  • 9.5.3. Colorectal Cancer
  • 9.5.4. Prostate Cancer
  • 9.5.5. Leukemia
  • 9.5.6. Lymphoma
  • 9.5.7. Ovarian Cancer
  • 9.5.8. Pancreatic Cancer
  • 9.5.9. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 9.6.1. Oral
  • 9.6.2. Parenteral
  • 9.6.3. Others
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 9.7.1. Capsules/Tablets
  • 9.7.2. Injections
  • 9.7.3. Others
• 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 9.8.1. Retail Pharmacies
  • 9.8.2. Hospital Pharmacies
  • 9.8.3. Oncology Clinics & Infusion Centers
  • 9.8.4. Others
• 9.9. Market Attractiveness Analysis

10. Latin America Chemotherapy Drugs Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Drug Class
  • 10.2.3. By Indication
  • 10.2.4. By Route of Administration
  • 10.2.5. By Dosage Form
  • 10.2.6. By Distribution Channel
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 10.4.1. Alkylating Agents
  • 10.4.2. Antimetabolites
  • 10.4.3. Anti-tumour Antibiotics
  • 10.4.4. Topoisomerase Inhibitors
  • 10.4.5. Mitotic Inhibitors
  • 10.4.6. Plant Alkaloids
  • 10.4.7. Corticosteroids
  • 10.4.8. Miscellaneous Antineoplastic
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 10.5.1. Lung Cancer
  • 10.5.2. Breast Cancer
  • 10.5.3. Colorectal Cancer
  • 10.5.4. Prostate Cancer
  • 10.5.5. Leukemia
  • 10.5.6. Lymphoma
  • 10.5.7. Ovarian Cancer
  • 10.5.8. Pancreatic Cancer
  • 10.5.9. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 10.6.1. Oral
  • 10.6.2. Parenteral
  • 10.6.3. Others
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 10.7.1. Capsules/Tablets
  • 10.7.2. Injections
  • 10.7.3. Others
• 10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 10.8.1. Retail Pharmacies
  • 10.8.2. Hospital Pharmacies
  • 10.8.3. Oncology Clinics & Infusion Centers
  • 10.8.4. Others
• 10.9. Market Attractiveness Analysis

11. Middle East & Africa Chemotherapy Drugs Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Drug Class
  • 11.2.3. By Indication
  • 11.2.4. By Route of Administration
  • 11.2.5. By Dosage Form
  • 11.2.6. By Distribution Channel
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2032
  • 11.4.1. Alkylating Agents
  • 11.4.2. Antimetabolites
  • 11.4.3. Anti-tumour Antibiotics
  • 11.4.4. Topoisomerase Inhibitors
  • 11.4.5. Mitotic Inhibitors
  • 11.4.6. Plant Alkaloids
  • 11.4.7. Corticosteroids
  • 11.4.8. Miscellaneous Antineoplastic
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2024-2032
  • 11.5.1. Lung Cancer
  • 11.5.2. Breast Cancer
  • 11.5.3. Colorectal Cancer
  • 11.5.4. Prostate Cancer
  • 11.5.5. Leukemia
  • 11.5.6. Lymphoma
  • 11.5.7. Ovarian Cancer
  • 11.5.8. Pancreatic Cancer
  • 11.5.9. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2024-2032
  • 11.6.1. Oral
  • 11.6.2. Parenteral
  • 11.6.3. Others
• 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Dosage Form, 2024-2032
  • 11.7.1. Capsules/Tablets
  • 11.7.2. Injections
  • 11.7.3. Others
• 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2032
  • 11.8.1. Retail Pharmacies
  • 11.8.2. Hospital Pharmacies
  • 11.8.3. Oncology Clinics & Infusion Centers
  • 11.8.4. Others
• 11.9. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. F. Hoffmann-La Roche Ltd
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Product Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Celgene Corp
  • 12.3.3. Novartis AG
  • 12.3.4. Bristol-Myers Squibb Co
  • 12.3.5. Johnson & Johnson
  • 12.3.6. Sanofi
  • 12.3.7. Pfizer Inc.
  • 12.3.8. Eli Lilly & Company
  • 12.3.9. ImClone Systems Inc.
  • 12.3.10. GlaxoSmithKline
  • 12.3.11. AstraZeneca
  • 12.3.12. Schering-Plough
  • 12.3.13. Boehringer Ingelheim
  • 12.3.14. Bristol-Myers Squibb
  • 12.3.15. Teva Pharmaceuticals Industries
  • 12.3.16. E. Hoffmann-La Roche Ltd
  • 12.3.17. Merck & Co. Inc.
  • 12.3.18. Chemo Espana SL
  • 12.3.19. Amgen Inc
  • 12.3.20. Bayer AG
  • 12.3.21. Takeda Pharmaceutical Company Limited

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료